Johnson & Johnson professional education and development manager, David Jameson, discusses the current options in a practitioners’ armory when an astigmatic contact lens patient presents with presbyop ...
Tenpoint Therapeutics is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis Pharma, and LENZ Therapeutics, after getting FDA approval for its ...
The most common side effects were headache, impaired vision, and temporary eye pain or eye irritation. "The FDA approval of Yuvezzi represents a significant milestone for the millions of people in the ...
The US Food and Drug Administration has approved a landmark eye drop that uses a combined dose of medication to restore age-related near-sightedness, without the need for surgery, for a longer ...
Eye redness was not a commonly reported side effect in clinical trials of YUVEZZI. In BRIO I and BRIO II the reports of adverse events of ocular hyperemia (eye redness) were low. 1,2 In BRIO II, the ...
The FDA has approved YUVEZZI, the first dual-agent eye drop, to treat presbyopia, a leading cause of vision loss in adults. The medication uses a fixed-dose combination of carbachol (2.75%) and ...
The gradual loss of near vision that is a natural part of aging can be addressed by glasses, contact lenses, or even surgical procedures. A presbyopia eye drop developed by Tenpoint Therapeutics now ...
Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA approval (PDF) for Yuvezzi, a treatment for presbyopia, a common, age-related ...
Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that the U.S. Food and Drug ...
Yuvezzi is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. Phase III trials showed Yuvezzi significantly improved near visual acuity without ...
Yuvezzi is expected to be available in the second quarter of 2026. The Food and Drug Administration (FDA) has approved Yuvezzi ™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for ...
Although presbyopia is common and expected in people older than 40 years of age, its symptoms are nonspecific (blurred vision, eye strain or headache); therefore, careful consideration of differential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results